Healthcare
Polaryx Therapeutics, Inc. Common Stock(PLYX)
Live Price
Offline$2.32
+0.43% today
Window Change
-93.37%
Window
Feb 2, 2026 โ Jun 18, 2026
- Market Cap
- $230.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -18.8%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 96 bars ยท Feb 2, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Polaryx Therapeutics, Inc. Common Stock (PLYX) is a Healthcare stock with a market cap of $230.00M and listed on NASDAQ. The stock last traded around $2.32 and down 93.4% across the available one-year price window (Feb 2, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -18.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -18.8%, free cash flow -53.3% with operating margin 0.0% and ROIC -162.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PLYX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 3, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -18.8%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -25.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 3, 2026 | โ | +0.4% | -10.3% | โ |
2026 Mar 24, 2026 | +0.0% | -2.5% | +17.4% | -14.4% |
2026 Jan 27, 2026 | โ | -37.3% | -83.1% | -92.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PLYX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PLYX Max Drawdown
-93.54%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PLYX and SPY.
Company Overview
Polaryx Therapeutics, Inc. Common Stock
NASDAQ Global Market
Polaryx Therapeutics, Inc., operates as a biotech company that develops small molecule therapeutics for lysosomal storage disorders and neurodegenerative disorders. Its pipeline includes PLX-100, a combination of PLX-200 and a supplement for late infantile neuronal ceroid lipofuscinosis (LINCL) and other forms of NCL; PLX-200, a repurposed drug that is used to treat other diseases in adults and children; and PLX-300, a drug isolated from an edible plant that activates PPARa, which enhances production of transcription factor EB. The company was founded in 2014 and is based in Paramus, New Jersey.
- Leadership
- Alex Yang
- IPO Date
- Feb 2, 2026
- Employees
- 11
- Street Address
- South Tower
- Mailing
- Paramus, NJ, 07652
- Region
- Paramus, NJ, US
- Reporting Currency
- USD
- Investor Line
- (201) 940-7236
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 50.6
Growth
- Revenue
- 0.0%
- EPS
- -18.8%
- Free Cash Flow
- -53.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -207.0%
- ROIC
- -162.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 8.55
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.